<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Interdiscip Perspect Infect Dis</journal-id><journal-id journal-id-type="publisher-id">IPID</journal-id><journal-title>Interdisciplinary Perspectives on Infectious Diseases</journal-title><issn pub-type="ppub">1687-708X</issn><issn pub-type="epub">1687-7098</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19259329</article-id><article-id pub-id-type="pmc">2648620</article-id><article-id pub-id-type="doi">10.1155/2008/829101</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Insights into the Roles of Gut Microbes in Obesity</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sanz</surname><given-names>Yolanda</given-names></name><xref ref-type="aff" rid="I1"/><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Santacruz</surname><given-names>Arlette</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><name><surname>De Palma</surname><given-names>Giada</given-names></name><xref ref-type="aff" rid="I1"/></contrib></contrib-group><aff id="I1">Institute of Agrochemistry and Food Technology (IATA), Spanish National Research Council (CSIC), P.O. Box 73, Burjassot, 46100 Valencia, Spain</aff><author-notes><corresp id="cor1">*Yolanda Sanz: <email>yolsanz@iata.csic.es</email></corresp><fn fn-type="other"><p>Recommended by Vincent B. Young</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>3</day><month>12</month><year>2008</year></pub-date><volume>2008</volume><elocation-id>829101</elocation-id><history><date date-type="received"><day>11</day><month>6</month><year>2008</year></date><date date-type="rev-recd"><day>26</day><month>8</month><year>2008</year></date><date date-type="accepted"><day>2</day><month>10</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Yolanda Sanz et al.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Obesity is a major public health issue as it enhances the risk of suffering several chronic diseases of increasing prevalence. Obesity results from an imbalance between energy intake and expenditure, associated with a chronic low-grade inflammation. Gut microbes are considered to contribute to body weight regulation and related disorders by influencing metabolic and immune host functions. The gut microbiota as a whole improves the host's ability to extract and store energy from the diet leading to body weight gain, while specific commensal microbes seem to exert beneficial effects on bile salt, lipoprotein, and cholesterol metabolism. The gut microbiota and some probiotics also regulate immune functions, protecting the host form infections and chronic inflammation. In contrast, dysbiosis and endotoxaemia may be inflammatory factors responsible for developing insulin resistance and body weight gain. In the light of the link between the gut microbiota, metabolism, and immunity, the use of dietary strategies to modulate microbiota composition is likely to be effective in controlling metabolic disorders. Although so far only a few preclinical and clinical trials have demonstrated the effects of specific gut microbes and prebiotics on biological markers of these disorders, the findings indicate that advances in this field could be of value in the struggle against obesity and its associated-metabolic disorders.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. INTRODUCTION</title><p>Obesity is a major public health concernaffecting both the developed and the developing world. The obesity epidemic startedto grow in US in the 1980s, with values rising from 22.9% obese adults in 1988&#x02013;1994 to 30.5% in 1999&#x02013;2000 [<xref ref-type="bibr" rid="B1">1</xref>]. In 1996, the World Health Organization (WHO) together withnational Ministries of Health agreed to tackle obesity worldwide, but sincethen it has increased sharply, reaching values of at least 20% obese adults inmost US  states and European countries [<xref ref-type="bibr" rid="B2">2</xref>]. Obesity is detrimental to the quality of life and implieshigh health costs as a consequence of its associated morbidities. Overweightand obesity constitute risk factors for a number of chronic diseasesincluding diabetes, cardiovascular diseases,nonalcoholic fatty liver disease, cancer, and other immune-related disorderssuch as asthma and infections [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>Obesity results from a long-term positiveimbalance between energy intake and expenditure with excessive increase in bodyfat. Obesity and the associated disorders are also characterized by a state ofchronic, low-grade inflammation with abnormal cytokine and adipokine production[<xref ref-type="bibr" rid="B4">4</xref>]. Production of inflammatory immune mediators such as tumor-necrosis factor(TNF)-<italic>&#x003b1;</italic>, interleukin (IL)-6, IL-1<italic>&#x003b2;</italic>, CC-chemokine ligand 2 (CCL2 or monocyte chemotactic protein 1), and theproinflammatory adipokines leptin and resistin is usually high in these subjects,whereas production of the anti-inflammatory and insulin-sensitizing adipokineadiponectin is reduced [<xref ref-type="bibr" rid="B5">5</xref>]. Inflammation associated with obesity involvesdiverse signal transduction cascades including the nuclear factor kappa B (NF-<italic>&#x003ba;</italic>B)/IKK<italic>&#x003b2;</italic> system and the Jun N-terminal kinase (JNK) [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B6">6</xref>]. Leptin is the dominant long-term signal informing the brain of energystores and, together with insulin, is secreted upon ingestion thus inhibitingfood intake. However, human obesity is not commonly associated withleptin-deficiency but with leptin-resistance and increased levels of thisadipokine. Leptin seems to exert a proinflammatory effect by inducing theproduction of CCL2, proinflammatory cytokines (TNF-<italic>&#x003b1;</italic>, IL-6, and IL-12), and also typical T helper (Th) 1-cytokines (IL-2 and IFN<italic>&#x003b3;</italic>) involved in other chronic inflammatory andautoimmune disorders such as Crohn's disease [<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>].</p><p>Although susceptibility to definitive increasesin body weight is genetically determined, the environment also influences weightgain considerably. It is currently believed that macrosocial changes associatedwith regular intake of energy-dense foods and low-physical activity havecreated an obesogenic environment worldwide,constituting the cornerstone of the global obesity epidemic [<xref ref-type="bibr" rid="B8">8</xref>]. Traditional treatments based on calorie-restricted diets and increased physicalactivity have succeeded in controlling obesity to some extent [<xref ref-type="bibr" rid="B9">9</xref>]. Nevertheless, these strategies usually yield limitedand short-lived weight reductions and most people regain some of their weightloss [<xref ref-type="bibr" rid="B3">3</xref>]. Neither has pharmacological therapy fully succeeded in effectivelytreating obesity for long-term periods and also has a number of side-effects [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B10">10</xref>]. In this scenario, the identification of additional environmental factorsinvolved in energy regulation is critical with a view to develop more efficientintervention strategies.</p><p>The human gut is populated by an array ofbacterial species that coevolve with the host since birth and maintain dynamicinteractions with each other throughout life. The collective genome(microbiome) of the gut microbiota contains at least 100 times as many genes asthe human genome, with most serving human physiological functions [<xref ref-type="bibr" rid="B11">11</xref>]. The metabolic role of the gut microbiota isessential to the biochemical activity of the human body, resulting in salvageof energy, generation of absorbable compounds, and production of vitamins andother essential nutrients [<xref ref-type="bibr" rid="B12">12</xref>]. Thus, humans are considered superorganismswhose metabolism represents the combination of both microbial and humanfeatures [<xref ref-type="bibr" rid="B11">11</xref>]. The gut microbiota also regulates many aspects of innate andacquired immunity, protecting the host from pathogen invasion and chronicinflammation [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>]. In contrast, imbalances in the composition of gutmicrobiota have been associated with susceptibility to infections, immune-baseddisorders, and recently also with insulin resistance and body weight gain [<xref ref-type="bibr" rid="B15">15</xref>]. In the last decades, sound relationships between the composition of the gutmicrobiota and human health have been established, leading to the design ofdietary strategies to favor the prevalence of beneficial bacteria to maintain ahealthy status. These strategies include the administration of prebioticoligosaccharides, which stimulate the growth and/or metabolic activity ofbeneficial bacteria, and also of selected bacterial strains (probiotics) in theform of functional foods and supplements [<xref ref-type="bibr" rid="B16">16</xref>]. Herein, the current knowledge ofthe relationships between the composition and functions of the gut microbiotaand obesity is reviewed, including some studies intended to evaluate theeffects of probiotics and prebiotics in the management of metabolic disorders.</p></sec><sec sec-type="section" id="sec2"><title>2. GUT MICROBIOTA COMPOSITION, DIET,AND OBESITY</title><p>Obesity has been associated with increases inthe relative abundance of <italic>Firmicutes</italic> and proportional reductions in <italic>Bacteroidetes</italic> by comparisons between the distal gut microbiota of genetically obese (leptindeficient <italic>ob/ob</italic> mice) and lean mice, as well as of that of obese and lean humansubjects [<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>]. In addition, obese human adults submitted to a hypocaloricdiet (either low carbohydrate- or low fat-containing diet) showed significantincreases in fecal proportions of <italic>Bacteroidetes</italic> paralleled to weight loss over a one-year-long intervention in a few subjects [<xref ref-type="bibr" rid="B18">18</xref>]; nonetheless, species diversity was reported to remain constant. Studies on thececal microbiota of genetically obese mice and their lean littermates alsorelated a higher proportion of <italic>Archaea</italic> to obesity [<xref ref-type="bibr" rid="B17">17</xref>]. These relationships between obesity and the gut microbiotacomposition were first based on DNA sequence analysis of the total distal gutmicrobiome of mice and humans obtained from genomic libraries or directly bypyrosequencing. Of these microbial groups, <italic>Bacteroidetes</italic> and <italic>Firmicutes</italic> constitute thedominant bacterial subdivision (&#x0003e;99%) among the 70 bacterial subdivisions identifiedin distal gut, while <italic>Methanobrevibacteriumsmithii</italic> constitutes the most prominent methanogenic archaeon among the 13 <italic>Archaea</italic> divisions reported to date basedon 16S ribosomal DNA sequencing data [<xref ref-type="bibr" rid="B11">11</xref>]. More recently, diet-induced obesityin animal models has been associated with increases in the proportion of asingle-uncultured clade within the <italic>Mollicutes</italic> class of <italic>Firmicutes</italic>, which was alsodiminished by subsequent dietary manipulations to limit weight gain, showingmore specific relationships between obesity and components of the gutmicrobiota [<xref ref-type="bibr" rid="B19">19</xref>]. A study of a Chinese family, comprising 3 males and 4 females,also related the lowest <italic>Bacteroidetes</italic> to <italic>Firmicutes</italic> ratio to the overweightindividual, and demonstrated a high degree of interpersonal variation in thisvalue, ranging from 0.26 to 1.36 [<xref ref-type="bibr" rid="B20">20</xref>].</p><p>Differences in fecal microbiota compositionwere shown to predict overweight in children early in life. Children maintainingnormal weight showed a greater number of bifidobacteria, while childrenbecoming overweight showed a greater number of <italic>Staphylococcus aureus</italic> in feces during infancy [<xref ref-type="bibr" rid="B21">21</xref>]. Although theselected population group included children prone to allergy, who may show thedescribed microbial aberrancies, the obtained results are also in accordancewith the protective role attributed to breast-milk against developing obesitylater in life [<xref ref-type="bibr" rid="B22">22</xref>], and the predominance of bifidobacteria in thegut of breastfed babies [<xref ref-type="bibr" rid="B23">23</xref>]. Shifts in composition of animal and human gutbacteria in response to dietary changes (a high protein/low carbohydrate orhigh-fat intake) have also been shown to alter microbial composition andactivity in the large intestine that, in turn, could exert an impact on health [<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B24">24</xref>]. Obese humans submitted to a dietary intervention, based on reducingcarbohydrate intake and increasing protein intake, showed reductions inpopulations of <italic>Bifidobacterium</italic>, and <italic>Roseburia</italic> spp. and <italic>Eubacterium rectale</italic> subgroups of clostridial cluster XIVa whencarbohydrate intake was decreased, while no differences were detected in <italic>Bacteroide</italic>s or other clostridialclusters [<xref ref-type="bibr" rid="B24">24</xref>]. The abundance of <italic>Roseburia</italic> spp. and <italic>E. rectale</italic> groupcorrelated well with the decline in fecal butyrate as carbohydrate intake wasreduced; however, relationships to body weight were not established. Recentstudies on the evolution of mammals and their gut microbes pointed out that theacquisition of a new diet is a fundamental driver for changes in gut bacterialdiversity, which increases from carnivory to omnivory to herbivory [<xref ref-type="bibr" rid="B25">25</xref>]. Alterationsin gut microbiota composition associated with genetic or diet-induced obesityhave also been shown to be reversible by oral transfer of the gut microbiotafrom lean mice to a germ-free recipient [<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B26">26</xref>] or by administration ofprebiotic substrates to animal models at least over short-term periods [<xref ref-type="bibr" rid="B27">27</xref>]. Therefore, it seems likely that a combination of environmental (e.g. diet) and genetic factors contributes to defining uniquecombinations of bacteria within an individual, which could favor either anobese or lean phenotype. In this context, some authors argue that both antibioticsand probiotics have demonstrated to act as growth promoters when used in animalfeeding and, therefore, could contribute to current human obesity [<xref ref-type="bibr" rid="B28">28</xref>]. However, while antibiotics reduce gut microbiota populations, probioticsrestores their levels. Therefore, their common effect on animal weight gain canbe only a consequence of their common role in preventing infections. Bycontrast, other scientists consider that the intentional manipulation of thecomposition of gut microbiota via dietary strategies is a possible tool torevert or prevent overweight and particularly metabolic-associated disorders[<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>]. Although this line of research is still in its infancy, in thefollowing sections we summarize current evidence on the mechanisms of action ofgut microbiota on metabolic and immune aspects of obesity and the consequencesof its dietary manipulation by pro- and prebiotics.</p></sec><sec sec-type="section" id="sec3"><title>3. INFLUENCE OF THE GUT MICROBIOTA ONENERGY METABOLISM</title><p>The gut microbiota is considered a criticalfactor, together with lifestyle, involved in energy metabolism and obesity. Germ-free mice colonized by the distal gut microbiota of conventionally raisedmice produced a remarkable increase (60%) in body fat within 10&#x02013;14 days, althoughfeed consumption was reduced compared to the control germ-free mice [<xref ref-type="bibr" rid="B29">29</xref>]. This process also stimulated the synthesis ofleptin, and produced faster glycemia and insulinemia, paralleled to body-fatincrease [<xref ref-type="bibr" rid="B29">29</xref>]. The microbial colonization was demonstrated to increase thehost's ability to both harvest energy from the diet and store this energy inadypocites. This is thought to be achieved by diverse mechanisms includingimprovement of diet macronutrient utilization, generation of metabolitesinvolved in energy balance and regulation of host gene expression. Commensalbacteria have specialized sets of hydrolyses and transporters to digestnutrients, like complex polysaccharides, that would, otherwise, be inaccessibleto humans. These are the main energy sources for bacteria colonizing the largeintestine and confer them a competitive advantage over transient bacteria. Themicrobial fermentation of undigested dietary compounds can provideapproximately 10% of the daily energy supply in omnivores and up to 70% inherbivores [<xref ref-type="bibr" rid="B30">30</xref>]. The degradation of matrix and other dietary polysaccharides(xylans, manans, pectins, starch, and inulin) as well as host mucins lead  tothe generation of intermediate products (lactate, succinate, etc.) and finallyshort-chain fatty acids (SCFA), including butyrate, acetate, and propionate,which are almost completely absorbed along the gastrointestinal tract (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The ability to degrade highly insoluble polymeric substrates, such ascellulose and mucin, seems to be limited to a subset of primary microbedegraders in the large intestine and requires the expression of specificsubstrate attachment, degradation, and uptake systems like the so-calledcellulosome complex. In fact, cellulolytic species have been shown to formbiofilm associations with plant surfaces invitro, integrated by a higher fraction of <italic>Firmicutes</italic> and a smaller fraction of <italic>Bacteroides,</italic> which suggestsa more prominent role of the former bacterial group in energy harvest from thediet by facilitating complex polysaccharide utilization [<xref ref-type="bibr" rid="B31">31</xref>]. Severalclostridial clusters of <italic>Firmicutes</italic> are important butyrate-producing bacteria in the distal gut, such as <italic>Roseburia, E. rectale, Eubacterium halli,</italic> and <italic>Anaerostipes caccae,</italic> most ofwhich are included in clostridial cluster XIVa [<xref ref-type="bibr" rid="B31">31</xref>]. Acetogenesis is anothermetabolic attribute of relevance to obesity identified in this clostridialcluster [<xref ref-type="bibr" rid="B31">31</xref>], which could partly explain the inverse relationship between <italic>Firrmicutes</italic> and body weight reductionsin previous human intervention studies [<xref ref-type="bibr" rid="B18">18</xref>]. Soluble and less complexoligosaccharides such as starch and fructooligosaccharides can be utilized byother gut microbes such as <italic>Bacteroides</italic> and <italic>Bifidobacterium,</italic> which could alsocontribute to the generation of intermediary metabolites and finally to SCFA(<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>Although butyrate-producing bacteria wouldappear to be related to higher gut metabolic  activity leading to overweight, butyrate isextensively utilized by enterocytes and generally regarded as a healthy metabolite[<xref ref-type="bibr" rid="B32">32</xref>]. The main role of butyrate is to fuel enterocytes, covering up to 70% of their energy needs and contributing toepithelial cell growth regulation and differentiation (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Butyrate alsoexerts anti-inflammatory effects and seems to contribute to glucagon-likepeptide 1 (GLP-1) generation, which is involved in satiety, by promotingdifferentiation of stem cells into positive GLP-1 L cells. Altogether, this mayhave beneficial effects on obese-prone subjects [<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>]. Unlike butyrate, acetateand propionate generated in intestinal lumen can reach the blood stream and theliver through the portal vein (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Acetate can contribute to lipid andcholesterol synthesis in the liver by activating the cytosolic acetyl S CoAsynthetase 2, while propionate may inhibit lipid synthesis from acetate at least in rat hepatocytes [<xref ref-type="bibr" rid="B34">34</xref>]. In fact, high-propionate production throughfermentation of starch or fructans has been associated with serum and livercholesterol reduction in rats and the acetate to propionate ratio in portalblood, proposed as a possible maker of the effects of these dietary ingredientson lipid metabolism [<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B36">36</xref>]. Nevertheless, acetate administered at a high doseto rats and rat hepatocytes also induced AMP kinase and/or reduced SREBP-1cexpression related to lipogenesis inhibition, therefore further studies shouldbe carried out in humans to verify its positive or negative influences on lipidmetabolism [<xref ref-type="bibr" rid="B37">37</xref>].</p><p>In addition to SCFA, hydrogen is produced by polysaccharide-degradingspecies and its further utilization by methanogens, acetogens and sulfate-reducinggut microbes also activates the metabolism and growth of  polysaccharide-degradingbacteria  (<xref ref-type="fig" rid="fig1">Figure 1</xref>). <italic>Archaea</italic>, whichare the main gut methanogenic microorganisms, were also overrepresented ingenetically obese mice as compared to their lean littermates and were relatedto a greater capacity to promote adiposity when transferred to germ-freerecipients [<xref ref-type="bibr" rid="B38">38</xref>]. <italic>Eubacterium dolichum</italic>,a human <italic>Mollicute</italic>, was also shown tofavor import and processing of simple sugars in subjects under a Western-stylediet, partly explaining its association and that of <italic>Firmicutes</italic> division with obesity [<xref ref-type="bibr" rid="B19">19</xref>]. In addition, cross-feedingmechanisms between components of the gut microbiota have been identified atdifferent stages of the utilization of complex energy-rich polysaccharides. Thus, <italic>B. adolescentis</italic> can degradestarch, generating intermediate products (lactate and acetate) that can beutilized by butyrate-forming bacteria such as <italic>E. hallii</italic> to generate butyrate [<xref ref-type="bibr" rid="B39">39</xref>] or by other intestinalbacterial groups that convert lactate into propionate by the acrylate pathway [<xref ref-type="bibr" rid="B40">40</xref>]. Coinoculation of <italic>M. smithii</italic> and <italic>B. thetaiotaomicron</italic> into germ-free miceshowed that <italic>M. smithii</italic> directs <italic>B. thetaiotaomicron</italic> to focus onfermentation of dietary fructans to acetate, whereas <italic>B. thetaiotaomicron</italic>-derived formate is used by <italic>M. smithii</italic> for methanogenesis. Moreover, <italic>B. thetaiotaomicron-M. smithii</italic> cocolonization produced asignificant increase in host adiposity compared with monoassociated, or <italic>B. thetaiotaomicron-D. piger</italic> biassociated animals [<xref ref-type="bibr" rid="B41">41</xref>]. These studies emphasize the role of interactive setsof microbes, rather than the role of individual microorganism within the gutecosystem in energy-metabolism and body weight regulation. This makes it farmore complex to identify those that are critical to obesity control through dietarystrategies.</p><p>The gut microbiota may also influence energybalance by modifying gene expression of host-related metabolic functions. Angiogenesis, which is primarily involved in distributing nutrients toperipheral tissues, was shown to depend on the gut microbial colonizationprocess.  Although capillary networkformation was arrested in adult germ-free mice, this developmental processrestarted and was completed within 10 days after colonization with a completemicrobiota harvested from conventionally raised mice, or with <italic>Bacteroidesthetaiotaomicron</italic> [<xref ref-type="bibr" rid="B42">42</xref>]. Commensal bacteria, such as <italic>B. thetaiotaomicron,</italic> have also been shown to induce expression of hostmonosaccharide transporters in monocolonized mice [<xref ref-type="bibr" rid="B43">43</xref>]. This would lead toincreasing the absorption of monosaccharides and SCFA and, thereby, promote the novo synthesis of lipids in theliver. In addition, the microbial colonization of germ-free mice increasedliver expression of two key enzymes involved in the de novo fatty acidbiosynthetic pathways, acetyl-CoA carboxylase  and fatty acid synthase, as well asthe transcriptional factors ChREBP and SREBP-1, which are involved inhepatocyte lipogenic responses to insulin and glucose [<xref ref-type="bibr" rid="B29">29</xref>]. Unlike colonized mice, germ-free animals wereprotected against the obesity that develops after consuming a Western-style,high-fat, sugar-rich diet by increasing fatty acid metabolism via twocomplementary mechanisms: (i) increasing levels of circulating fasting-inducedadipose factor (Fiaf), which inhibits lipoprotein lipase thereby limiting fatstorage in adipocytes and promoting fat oxidation in muscle; and (ii)increasing skeletal muscle and liver levels of phosphorylated AMP-activatedprotein kinase and its downstream targets, involved in fatty acid <italic>&#x003b2;</italic>  oxidation [<xref ref-type="bibr" rid="B44">44</xref>].</p><p>Commensal gut microbiota and probiotics couldalso regulate serum lipids by taking part in bile acid metabolism. Bile saltsare highly effective detergents that promote solubilization andabsorption of dietary lipids throughout the intestine. The majorbile salt modifications of microbial origin in the human gut include deconjugation,oxidation of diverse hydroxyl groups and 7 <italic>&#x003b1;</italic>/<italic>&#x003b2;</italic>-dehydroxylation [<xref ref-type="bibr" rid="B45">45</xref>]. Certain probioticshave been shown to decrease serum cholesterol levels by means oftheir bile salt hydrolytic activity [<xref ref-type="bibr" rid="B46">46</xref>]. Significant bile salthydrolysis occurring in the proximal and terminal ileum reduces bile saltuptake through high-affinity transport system and lipidsolubilization. This also leads to an increase in bile-acid excretion in fecesand bile-acid synthesis from cholesterol [<xref ref-type="bibr" rid="B45">45</xref>]. For example, administration of <italic>L. acidophilus</italic> ATCC 43121 seemed to reduceserum cholesterol levels by bile acid deconjugation and dehydroxylationreactions during cholesterol metabolism in hypercholesterolemia-induced rats [<xref ref-type="bibr" rid="B46">46</xref>]. This intervention resulted in increased excretion of total fecal acid sterolsand secondary bile acids (deoxycholic and lithocholic acids), and a reductionof primary bile acids (cholic and chenodeoxycholic acids). Particularly, thereduction in blood cholesterol levels was related to the increase in theinsoluble bile acid, lithocholic acid. More recently, metabolomic studies haveindicated that supplementation of <italic>Lactobacillusparacasei</italic> NCC2461 or <italic>Lactobacillusrhamnosus</italic> NCC4007 probiotics to germ-free mice colonized with human babyflora-induced changes in hepatic-lipid metabolism and enterohepaticrecirculation of bile acids that led to a decrease in the plasma concentrationsof lipoproteins VLDL and LDL, when compared to controls [<xref ref-type="bibr" rid="B47">47</xref>]. <italic>Lactobacillus</italic> supplementation also decreased fecal excretion of bile acids probably due totheir accumulation in <italic>Lactobacillus</italic> probiotic cells. Probioticadministration also led to reductions of acetate in cecal content as well as ofthe hepatic acetate to propionate ratio, which was related to a reduction in serumlipids [<xref ref-type="bibr" rid="B47">47</xref>]. Furthermore, studies in vitro indicated that fecal commensal bacteria, but not probiotics, wereable to reduce cholesterol to coprostanol and thus increasing its excretion infeces [<xref ref-type="bibr" rid="B48">48</xref>].</p><p>Some probiotic strains of the genus <italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic> were also reported to synthesize conjugatedlinolenic acid (CLA) from polyunsaturated fatty acids of soy oil, which reducesserum lipids and cholesterol in liver. One example of these bacteria is <italic>Lactobacillus rhamnosus</italic> PL60, which is ahuman isolate that produces t10, c12-conjugated linoleic acid and was found to exertan antiobesity effect on diet-induced obese mice after 8 weeks of feeding. Thisstrain reduced body weight without reducing energy intake, and caused aspecific reduction of white adipose tissue without producing liver steatosis,which is a common side effect of CLA [<xref ref-type="bibr" rid="B49">49</xref>].</p></sec><sec sec-type="section" id="sec4"><title>4. IMMUNE ROLE OF THE GUT MICROBIOTAAND OBESITY</title><p>Obesity is considered an inflammatory disorder,which affects both innate and adaptive immunity and favors the development ofother disorders such as type-2 diabetes and cardiovascular diseases [<xref ref-type="bibr" rid="B50">50</xref>]. Infact, chronic activation of innate immunity is regarded as a risk factor as itfavors the development of these disorders, which could also be influenced by thegut microbiota [<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B51">51</xref>]. The gut microbiota largely regulates innate andadaptive immunity, influencing local and systemic responses (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The recognition ofbacterial components through pattern-recognition receptors (PRRs), such as toll-likereceptors (TLRs) of innate immune cells, is considered to be the starting pointof immunity, informing the immunocompetent cells to respond properly to eachenvironmental stimulus (e.g., pathogens or harmless microbes) [<xref ref-type="bibr" rid="B13">13</xref>]. TLR-4recognizes lipopolysaccharide (LPS) from Gram-negative bacteria, while TLR-2recognizes lipopeptides and lipoproteins from various pathogens, andpeptidoglycan and lipoteichoic acid from Gram-positive bacteria (<xref ref-type="fig" rid="fig2">Figure 2</xref>) [<xref ref-type="bibr" rid="B52">52</xref>]. Upon ligand binding, TLR interacts with different adaptor proteins (MyD88,TIRAP/Mal, TRIF, and TRAM) activating the transcription of differentdownstream effector systems, such as the mitogen-activated kinases (MAPK), theNF-<italic>&#x003ba;</italic>B/IKK<italic>&#x003b2;</italic> system, and the activator protein-1 (AP-1) withproduction of cytokines and diverse immune mediators [<xref ref-type="bibr" rid="B53">53</xref>]. Cytokines such asTNF-<italic>&#x003b1;</italic>, IL-1<italic>&#x003b2;</italic>, and IL-6 are the major proinflammatorymediators produced in response to TLR-4 stimulation by endotoxin (LPS) as wellas those increased in obese and insulin-resistant patients (<xref ref-type="fig" rid="fig2">Figure 2</xref>) [<xref ref-type="bibr" rid="B54">54</xref>]. Unlikepathogenic microbes, commensal bacteria maintain a peaceful relationship withtheir hosts by producing a transient activation of the NF-<italic>&#x003ba;</italic>B cascade or its suppression by diversemechanisms including (i) promotion of nuclear export of NF-<italic>&#x003ba;</italic>B subunit relA in complex with PPAR-<italic>&#x003b3;</italic> [<xref ref-type="bibr" rid="B55">55</xref>], (ii) inhibition of I<italic>&#x003ba;</italic>B ubiquitination and degradation in epithelialcells [<xref ref-type="bibr" rid="B56">56</xref>], (iii) regulation of TLR expression and upregulation of the negativeregulator Tollip protein [<xref ref-type="bibr" rid="B57">57</xref>], and (iv) induction of anti-inflammatory cytokines such as IL-10 [<xref ref-type="bibr" rid="B58">58</xref>]. TLRs and derived cytokines also play a pivotalrole in linking innate and adaptive immunity through exerting action on T-cellsand particularly on dedritic cells (DCs), keeping a physiological Th1/Th2balance [<xref ref-type="bibr" rid="B13">13</xref>]. Th1-polarized responses characterized by overproduction of IFN-<italic>&#x003b3;</italic>, IL-2, and IL-12 cytokines are associated withclearance of intracellular pathogens as well as with chronic diseases includingdiabetes and obesity. Most TLR-activated DCs induce differentiation of na&#x000ef;veCD4+ T cells into Th1 cells, while TLR2-activated DCs promote thedifferentiation of Th2-cells or regulatory T cells by producing high levels of anti-inflammatory cytokineIL-10 which could help to counteract the inflammatory status associated withobesity [<xref ref-type="bibr" rid="B58">58</xref>]. Interestingly, TLRs have been identified not only in innate andadaptive immune cells but also in insulin-responsive tissues such as the adiposetissue, muscle, and liver, suggesting a connection between immunity, microbialstimulation, and metabolism [<xref ref-type="bibr" rid="B59">59</xref>]. Diet-induced and genetically obese mice (<italic>ob/ob</italic> or <italic>db/db</italic>) showed asignificant upregulation of expression of TLR-1 to -9 in adipocytes andpreadipocytes along with higher cytokine production upon stimulation [<xref ref-type="bibr" rid="B60">60</xref>]. In particular, it isknown that TLR-4 can be activatedby both lipopolysaccharide (LPS) and dietary-saturated fatty acidsinducing upregulation of common intracellular inflammatory pathways,such as JNK and NF-<italic>&#x003ba;</italic>B in adipocytes and macrophages, related to theinduction of insulin resistance and increased adiposity (<xref ref-type="fig" rid="fig2">Figure 2</xref>) [<xref ref-type="bibr" rid="B51">51</xref>]. Conversely, adipocyte-specificknockdown of TLR4 prevented cytokine expression induced either by LPS orsaturated fatty acids and similar effects were shown in macrophages. With some exceptions,loss-of-functional mutation in TLR-4 also prevented diet-induced obesity andinsulin resistance in vivo micemodels [<xref ref-type="bibr" rid="B51">51</xref>]. Recently, metabolic endotoxaemia, characterized by anincrease in serum LPS levels, has been demonstrated to be an inflammatoryfactor, causative of body weight gain, insulin resistance, and diabetes inhigh-fat fed animal models [<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B61">61</xref>]. In contrast, theinhibition of the gut microbiota by antibiotic administration (norfloxacin andampicillin) in two different mouse models of insulin resistance resulted inreduced serum LPS levels, low-grade inflammation, obesity, and type-2 diabetes,demonstrating the link between the gut microbiota and certain metabolicdisorders [<xref ref-type="bibr" rid="B15">15</xref>]. LPS stimulation also produces a cytokine-mediated increase inplasma lipid levels by increasing the synthesis of VLDL lipoproteins in theliver and inhibiting lipoprotein lipase. In fact, mobilization of lipid storesis considered a mechanism to fuel the host's response against infections;moreover, lipoproteins also seem to help fight against infection by binding andneutralizing LPS [<xref ref-type="bibr" rid="B62">62</xref>].  Therefore, commonresponses can be induced by &#x0201c;pathogenic lipid nutrients&#x0201d; and microorganismsmainly related to TLR-4-signaling and proinflammatory cytokine and genetranscription activation pathways. In this scenario, one can hypothesize that shiftsin gut microbiota composition caused by a high-saturated fatty acid-containingdiet [<xref ref-type="bibr" rid="B27">27</xref>],together with dietary lipids,could constitute synergic TLR signals, thus contributing to the amplificationof inflammation occurring in obesity. Consequently, it has been suggested that probioticsand prebiotics with anti-inflammatory properties could be of help in the fightagainst obesity andassociated disorders, as reported in other chronic inflammatory diseases [<xref ref-type="bibr" rid="B53">53</xref>]. Although few specific studies have proven sucha hypothesis so far, the administration of the probiotic VSL3# was demonstratedto exert a preventive effect against type-1 diabetes in a nonobese diabeticmice model by immunomodulatory mechanisms, inducing IL-10 production in Peyer patches,and spleen and its expression in the pancreas [<xref ref-type="bibr" rid="B63">63</xref>]. In addition, <italic>Lactobacillus</italic> culture-supernatants wereshown to reduce in vitro leptinproduction by adipocytes, thereby reducing IFN-<italic>&#x003b3;</italic> production by lymphocytes and exerting ananti-inflammatory role [<xref ref-type="bibr" rid="B64">64</xref>]. Oral administration of a functional food productcontaining <italic>L. plantarum</italic> 299v to heavysmokers for six weeks led to a decrease in leptin, systolic blood pressure, andfibrinogen, which was attributed to the anti-inflammatory effects of thisprobiotic, suggesting it would be able to reduce cardiovascular risk [<xref ref-type="bibr" rid="B65">65</xref>]. Incontrast, oral administration of <italic>Lactobacillusacidophilus</italic> and <italic>Bifidobacteriumlongum</italic> strains to human subjects did not influence serum leptin levels [<xref ref-type="bibr" rid="B66">66</xref>]. The administration of a prebiotic (oligofructose) to high-fat-diet fed mice wasalso shown to restore <italic>Bifidobacterium</italic> levels, which positively correlated with improved glucose tolerance,glucose-induced insulin secretion, and normalization of inflammatory tone bydecreasing endotoxaemia in plasma and proinflammatory cytokines in adiposetissue [<xref ref-type="bibr" rid="B27">27</xref>].</p></sec><sec sec-type="section" id="sec5"><title>5. CONCLUSIONS AND FUTURE CHALLENGES</title><p>Gut microbes are viewed as novel factorsinvolved in host physiology and body weight regulation by driving a number ofmetabolic and immune functions. The initial association of the microbialcolonization process of the germ-free intestine with body weight gain conferreda negative role to gut microbes with respect to obesity. Further, relationshipsestablished between a specific microbiota structure and a lean or obesephenotype have suggested that different microbes may influence body weightdifferently, and species- and stain-specific functions are being defined. Inaddition, endotoxaemia and dysbiosis have been identified as inflammatoryfactors responsible for insulin resistance and body weight, thereby returningto the concept that a healthy microbiota may be beneficial in preventing thesedisorders. Although the cause-effect relationships of the gut microbiota withobesity remain unclear and a limited number of in vivo trials have been done to assess the effects of specificmicrobial strains (commensals and probiotics), and prebiotics on metabolicdisorders, the knowledge provided by these studies constitutes a breakthroughin the identification of their etiology. Further work based on systems biologycoupled with &#x0201c;omic&#x0201d; technologies (metagenomics, trancriptomics, andmetabolomics) will be critical to shed light on the roles of specific sets ofmicrobes on metabolic disorders, with a view to design more efficientdietary-based strategies to reduce their risk.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>This work was supported by Grants AGL2007-66126-C03-01/ALIand Consolider Fun-<italic>C</italic>-Food CSD2007-00063 from the Spanish Ministry ofScience and Innovation and AP 002/07 from Conseller&#x000ed;a de Sanidad, Valencia,Spain. The scholarships to A. Santacruz from CONACYT (Mexico)and to G. De Palma from CSIC (Spain)are fully acknowledged.</p></ack><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Flegal</surname><given-names>KM</given-names></name><name><surname>Carroll</surname><given-names>MD</given-names></name><name><surname>Ogden</surname><given-names>CL</given-names></name><name><surname>Johnson</surname><given-names>CL</given-names></name></person-group><article-title>Prevalence and trends in obesity among US adults, 1999-2000</article-title><source><italic>The Journal of the American Medical Association</italic></source><year>2002</year><volume>288</volume><issue>14</issue><fpage>1723</fpage><lpage>1727</lpage></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>WPT</given-names></name></person-group><article-title>The epidemiology of obesity: the size of the problem</article-title><source><italic>Journal of Internal Medicine</italic></source><year>2008</year><volume>263</volume><issue>4</issue><fpage>336</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">18312311</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amber</surname><given-names>V</given-names></name><name><surname>Bloom</surname><given-names>SR</given-names></name></person-group><article-title>Adiposity and the gut&#x02014;the role of gut hormones</article-title><source><italic>Current Nutrition &#x00026; Food Science</italic></source><year>2007</year><volume>3</volume><issue>1</issue><fpage>75</fpage><lpage>90</lpage></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tilg</surname><given-names>H</given-names></name><name><surname>Moschen</surname><given-names>AR</given-names></name></person-group><article-title>Adipocytokines: mediators linking adipose tissue, inflammation and immunity</article-title><source><italic>Nature Reviews Immunology</italic></source><year>2006</year><volume>6</volume><issue>10</issue><fpage>772</fpage><lpage>783</lpage><pub-id pub-id-type="pmid">16998510</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zeyda</surname><given-names>M</given-names></name><name><surname>Stulnig</surname><given-names>TM</given-names></name></person-group><article-title>Adipose tissue macrophages</article-title><source><italic>Immunology Letters</italic></source><year>2007</year><volume>112</volume><issue>2</issue><fpage>61</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">17719095</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fr&#x000fc;hbeck</surname><given-names>G</given-names></name></person-group><article-title>Intracellular signalling pathways activated by leptin</article-title><source><italic>Biochemical Journal</italic></source><year>2006</year><volume>393</volume><issue>1</issue><fpage>7</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">16336196</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aleffi</surname><given-names>S</given-names></name><name><surname>Petrai</surname><given-names>I</given-names></name><name><surname>Bertolani</surname><given-names>C</given-names></name><etal/></person-group><article-title>Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells</article-title><source><italic>Hepatology</italic></source><year>2005</year><volume>42</volume><issue>6</issue><fpage>1339</fpage><lpage>1348</lpage><pub-id pub-id-type="pmid">16317688</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bellisari</surname><given-names>A</given-names></name></person-group><article-title>Evolutionary origins of obesity</article-title><source><italic>Obesity Reviews</italic></source><year>2008</year><volume>9</volume><issue>2</issue><fpage>165</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">18257754</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>LA</given-names></name><name><surname>Ochoa</surname><given-names>MC</given-names></name><name><surname>W&#x000e4;rnberg</surname><given-names>J</given-names></name><name><surname>Marti</surname><given-names>A</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>JA</given-names></name><name><surname>Marcos</surname><given-names>A</given-names></name></person-group><article-title>Treatment of obesity in children and adolescents. How nutrition can work?</article-title><source><italic>International Journal of Pediatric Obesity</italic></source><year>2008</year><volume>3</volume><issue>supplement 1</issue><fpage>72</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">18278636</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hays</surname><given-names>NP</given-names></name><name><surname>Galassetti</surname><given-names>PR</given-names></name><name><surname>Coker</surname><given-names>RH</given-names></name></person-group><article-title>Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventions</article-title><source><italic>Pharmacology &#x00026; Therapeutics</italic></source><year>2008</year><volume>118</volume><issue>2</issue><fpage>181</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">18423879</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>SR</given-names></name><name><surname>Pop</surname><given-names>M</given-names></name><name><surname>DeBoy</surname><given-names>RT</given-names></name><etal/></person-group><article-title>Metagenomic analysis of the human distal gut microbiome</article-title><source><italic>Science</italic></source><year>2006</year><volume>312</volume><issue>5778</issue><fpage>1355</fpage><lpage>1359</lpage><pub-id pub-id-type="pmid">16741115</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>G</given-names></name><name><surname>Sanders</surname><given-names>ME</given-names></name><name><surname>Gaskins</surname><given-names>HR</given-names></name><etal/></person-group><article-title>New scientific paradigms for probiotics and prebiotics</article-title><source><italic>Journal of Clinical Gastroenterology</italic></source><year>2003</year><volume>37</volume><issue>2</issue><fpage>105</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">12869879</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanz</surname><given-names>Y</given-names></name><name><surname>Nadal</surname><given-names>I</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>E</given-names></name></person-group><article-title>Probiotics as drugs against human gastrointestinal infections</article-title><source><italic>Recent Patents on Anti-Infective Drug Discovery</italic></source><year>2007</year><volume>2</volume><issue>2</issue><fpage>148</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">18221171</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Medina</surname><given-names>M</given-names></name><name><surname>Izquierdo</surname><given-names>E</given-names></name><name><surname>Ennahar</surname><given-names>S</given-names></name><name><surname>Sanz</surname><given-names>Y</given-names></name></person-group><article-title>Differential immunomodulatory properties of <italic>Bifidobacterium logum</italic> strains: relevance to probiotic selection and clinical applications</article-title><source><italic>Clinical &#x00026; Experimental Immunology</italic></source><year>2007</year><volume>150</volume><issue>3</issue><fpage>531</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">17956582</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cani</surname><given-names>PD</given-names></name><name><surname>Bibiloni</surname><given-names>R</given-names></name><name><surname>Knauf</surname><given-names>C</given-names></name><etal/></person-group><article-title>Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice</article-title><source><italic>Diabetes</italic></source><year>2008</year><volume>57</volume><issue>6</issue><fpage>1470</fpage><lpage>1481</lpage><pub-id pub-id-type="pmid">18305141</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rastall</surname><given-names>RA</given-names></name><name><surname>Maitin</surname><given-names>V</given-names></name></person-group><article-title>Prebiotics and synbiotics: towards the next generation</article-title><source><italic>Current Opinion in Biotechnology</italic></source><year>2002</year><volume>13</volume><issue>5</issue><fpage>490</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">12459343</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ley</surname><given-names>RE</given-names></name><name><surname>B&#x000e4;ckhed</surname><given-names>F</given-names></name><name><surname>Turnbaugh</surname><given-names>P</given-names></name><name><surname>Lozupone</surname><given-names>CA</given-names></name><name><surname>Knight</surname><given-names>RD</given-names></name><name><surname>Gordon</surname><given-names>JI</given-names></name></person-group><article-title>Obesity alters gut microbial ecology</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2005</year><volume>102</volume><issue>31</issue><fpage>11070</fpage><lpage>11075</lpage><pub-id pub-id-type="pmid">16033867</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ley</surname><given-names>RE</given-names></name><name><surname>Turnbaugh</surname><given-names>PJ</given-names></name><name><surname>Klein</surname><given-names>S</given-names></name><name><surname>Gordon</surname><given-names>JI</given-names></name></person-group><article-title>Microbial ecology: human gut microbes associated with obesity</article-title><source><italic>Nature</italic></source><year>2006</year><volume>444</volume><issue>7122</issue><fpage>1022</fpage><lpage>1023</lpage><pub-id pub-id-type="pmid">17183309</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turnbaugh</surname><given-names>PJ</given-names></name><name><surname>B&#x000e4;ckhed</surname><given-names>F</given-names></name><name><surname>Fulton</surname><given-names>L</given-names></name><name><surname>Gordon</surname><given-names>JI</given-names></name></person-group><article-title>Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome</article-title><source><italic>Cell Host &#x00026; Microbe</italic></source><year>2008</year><volume>3</volume><issue>4</issue><fpage>213</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">18407065</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Symbiotic gut microbes modulate human metabolic phenotypes</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2008</year><volume>105</volume><issue>6</issue><fpage>2117</fpage><lpage>2122</lpage><pub-id pub-id-type="pmid">18252821</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kalliom&#x000e4;ki</surname><given-names>M</given-names></name><name><surname>Collado</surname><given-names>MC</given-names></name><name><surname>Salminen</surname><given-names>S</given-names></name><name><surname>Isolauri</surname><given-names>E</given-names></name></person-group><article-title>Early differences in fecal microbiota composition in children may predict overweight</article-title><source><italic>American Journal of Clinical Nutrition</italic></source><year>2008</year><volume>87</volume><issue>3</issue><fpage>534</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">18326589</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wabitsch</surname><given-names>M</given-names></name></person-group><article-title>Overweight and obesity in European children and adolescents: causes and consequences, treatment and prevention: an introduction</article-title><source><italic>European Journal of Pediatrics</italic></source><year>2000</year><volume>159</volume><issue>1</issue><fpage>S5</fpage><lpage>S7</lpage><pub-id pub-id-type="pmid">11011951</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fanaro</surname><given-names>S</given-names></name><name><surname>Chierici</surname><given-names>R</given-names></name><name><surname>Guerrini</surname><given-names>P</given-names></name><name><surname>Vigi</surname><given-names>V</given-names></name></person-group><article-title>Intestinal microflora in early infancy: composition and development</article-title><source><italic>Acta Paediatrica</italic></source><year>2003</year><volume>91</volume><issue>441</issue><fpage>48</fpage><lpage>55</lpage></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>SH</given-names></name><name><surname>Belenguer</surname><given-names>A</given-names></name><name><surname>Holtrop</surname><given-names>G</given-names></name><name><surname>Johnstone</surname><given-names>AM</given-names></name><name><surname>Flint</surname><given-names>HJ</given-names></name><name><surname>Lobley</surname><given-names>GE</given-names></name></person-group><article-title>Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces</article-title><source><italic>Applied and Environmental Microbiology</italic></source><year>2007</year><volume>73</volume><issue>4</issue><fpage>1073</fpage><lpage>1078</lpage><pub-id pub-id-type="pmid">17189447</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ley</surname><given-names>RE</given-names></name><name><surname>Hamady</surname><given-names>M</given-names></name><name><surname>Lozupone</surname><given-names>C</given-names></name><etal/></person-group><article-title>Evolution of mammals and their gut microbes</article-title><source><italic>Science</italic></source><year>2008</year><volume>320</volume><issue>5883</issue><fpage>1647</fpage><lpage>1651</lpage><pub-id pub-id-type="pmid">18497261</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turnbaugh</surname><given-names>PJ</given-names></name><name><surname>Ley</surname><given-names>RE</given-names></name><name><surname>Mahowald</surname><given-names>MA</given-names></name><name><surname>Magrini</surname><given-names>V</given-names></name><name><surname>Mardis</surname><given-names>ER</given-names></name><name><surname>Gordon</surname><given-names>JI</given-names></name></person-group><article-title>An obesity-associated gut microbiome with increased capacity for energy harvest</article-title><source><italic>Nature</italic></source><year>2006</year><volume>444</volume><issue>7122</issue><fpage>1027</fpage><lpage>1031</lpage><pub-id pub-id-type="pmid">17183312</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cani</surname><given-names>PD</given-names></name><name><surname>Neyrinck</surname><given-names>AM</given-names></name><name><surname>Fava</surname><given-names>F</given-names></name><etal/></person-group><article-title>Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia</article-title><source><italic>Diabetologia</italic></source><year>2007</year><volume>50</volume><issue>11</issue><fpage>2374</fpage><lpage>2383</lpage><pub-id pub-id-type="pmid">17823788</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raoult</surname><given-names>D</given-names></name></person-group><article-title>Obesity pandemics and the modification of digestive bacterial flora</article-title><source><italic>European Journal of Clinical Microbiology and Infectious Diseases</italic></source><year>2008</year><volume>27</volume><issue>8</issue><fpage>631</fpage><lpage>634</lpage></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>B&#x000e4;ckhed</surname><given-names>F</given-names></name><name><surname>Ding</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><etal/></person-group><article-title>The gut microbiota as an environmental factor that regulates fat storage</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2004</year><volume>101</volume><issue>44</issue><fpage>15718</fpage><lpage>15723</lpage><pub-id pub-id-type="pmid">15505215</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Flint</surname><given-names>HJ</given-names></name><name><surname>Bayer</surname><given-names>EA</given-names></name><name><surname>Rincon</surname><given-names>MT</given-names></name><name><surname>Lamed</surname><given-names>R</given-names></name><name><surname>White</surname><given-names>BA</given-names></name></person-group><article-title>Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis</article-title><source><italic>Nature Reviews Microbiology</italic></source><year>2008</year><volume>6</volume><issue>2</issue><fpage>121</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">18180751</pub-id></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leitch</surname><given-names>ECM</given-names></name><name><surname>Walker</surname><given-names>AW</given-names></name><name><surname>Duncan</surname><given-names>SH</given-names></name><name><surname>Holtrop</surname><given-names>G</given-names></name><name><surname>Flint</surname><given-names>HJ</given-names></name></person-group><article-title>Selective colonization of insoluble substrates by human faecal bacteria</article-title><source><italic>Environmental Microbiology</italic></source><year>2007</year><volume>9</volume><issue>3</issue><fpage>667</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">17298367</pub-id></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamer</surname><given-names>HM</given-names></name><name><surname>Jonkers</surname><given-names>D</given-names></name><name><surname>Venema</surname><given-names>K</given-names></name><name><surname>Vanhoutvin</surname><given-names>S</given-names></name><name><surname>Troost</surname><given-names>FJ</given-names></name><name><surname>Brummer</surname><given-names>R-J</given-names></name></person-group><article-title>Review article: the role of butyrate on colonic function</article-title><source><italic>Alimentary Pharmacology &#x00026; Therapeutics</italic></source><year>2008</year><volume>27</volume><issue>2</issue><fpage>104</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">17973645</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delzenne</surname><given-names>NM</given-names></name><name><surname>Cani</surname><given-names>PD</given-names></name><name><surname>Neyrinck</surname><given-names>AM</given-names></name></person-group><article-title>Modulation of glucagon-like peptide 1 and energy metabolism by inulin and oligofructose: experimental data</article-title><source><italic>The Journal of Nutrition</italic></source><year>2007</year><volume>137</volume><issue>11</issue><fpage>2547S</fpage><lpage>2551S</lpage><pub-id pub-id-type="pmid">17951500</pub-id></citation></ref><ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolever</surname><given-names>TMS</given-names></name><name><surname>Spadafora</surname><given-names>PJ</given-names></name><name><surname>Cunnane</surname><given-names>SC</given-names></name><name><surname>Pencharz</surname><given-names>PB</given-names></name></person-group><article-title>Propionate inhibits incorporation of colonic [1,2-13C]acetate into plasma lipids in humans</article-title><source><italic>American Journal of Clinical Nutrition</italic></source><year>1995</year><volume>61</volume><issue>6</issue><fpage>1241</fpage><lpage>1247</lpage><pub-id pub-id-type="pmid">7762524</pub-id></citation></ref><ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>HW</given-names></name><name><surname>Levrat-Verny</surname><given-names>M-A</given-names></name><name><surname>Coudray</surname><given-names>C</given-names></name><etal/></person-group><article-title>Class 2 resistant starches lower plasma and liver lipids and improve mineral retention in rats</article-title><source><italic>The Journal of Nutrition</italic></source><year>2001</year><volume>131</volume><issue>4</issue><fpage>1283</fpage><lpage>1289</lpage><pub-id pub-id-type="pmid">11285339</pub-id></citation></ref><ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delzenne</surname><given-names>NM</given-names></name><name><surname>Kok</surname><given-names>N</given-names></name></person-group><article-title>Effects of fructans-type prebiotics on lipid metabolism</article-title><source><italic>American Journal of Clinical Nutrition</italic></source><year>2001</year><volume>73</volume><issue>2, supplement</issue><fpage>456S</fpage><lpage>458S</lpage><pub-id pub-id-type="pmid">11157357</pub-id></citation></ref><ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakakibara</surname><given-names>S</given-names></name><name><surname>Yamauchi</surname><given-names>T</given-names></name><name><surname>Oshima</surname><given-names>Y</given-names></name><name><surname>Tsukamoto</surname><given-names>Y</given-names></name><name><surname>Kadowaki</surname><given-names>T</given-names></name></person-group><article-title>Acetic acid activates hepatic AMPK and reduces hyperglycemia in diabetic KK-A(y) mice</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>2006</year><volume>344</volume><issue>2</issue><fpage>597</fpage><lpage>604</lpage><pub-id pub-id-type="pmid">16630552</pub-id></citation></ref><ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Samuel</surname><given-names>BS</given-names></name><name><surname>Hansen</surname><given-names>EE</given-names></name><name><surname>Manchester</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Genomic and metabolic adaptations of <italic>Methanobrevibacter smithii</italic> to the human gut</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2007</year><volume>104</volume><issue>25</issue><fpage>10643</fpage><lpage>10648</lpage><pub-id pub-id-type="pmid">17563350</pub-id></citation></ref><ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Belenguer</surname><given-names>A</given-names></name><name><surname>Duncan</surname><given-names>SH</given-names></name><name><surname>Calder</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Two routes of metabolic cross-feeding between <italic>Bifidobacterium adolescentis</italic> and butyrate-producing anaerobes from the human gut</article-title><source><italic>Applied and Environmental Microbiology</italic></source><year>2006</year><volume>72</volume><issue>5</issue><fpage>3593</fpage><lpage>3599</lpage><pub-id pub-id-type="pmid">16672507</pub-id></citation></ref><ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>DJ</given-names></name><name><surname>Mackay</surname><given-names>WG</given-names></name><name><surname>Edwards</surname><given-names>CA</given-names></name><name><surname>Preston</surname><given-names>T</given-names></name><name><surname>Dodson</surname><given-names>B</given-names></name><name><surname>Weaver</surname><given-names>LT</given-names></name></person-group><article-title>Butyrate production from oligofructose fermentation by the human faecal flora: what is the contribution of extracellular acetate and lactate?</article-title><source><italic>British Journal of Nutrition</italic></source><year>2006</year><volume>96</volume><issue>3</issue><fpage>570</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">16925864</pub-id></citation></ref><ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Samuel</surname><given-names>BS</given-names></name><name><surname>Gordon</surname><given-names>JI</given-names></name></person-group><article-title>A humanized gnotobiotic mouse model of host-archaeal-bacterial mutualism</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2006</year><volume>103</volume><issue>26</issue><fpage>10011</fpage><lpage>10016</lpage><pub-id pub-id-type="pmid">16782812</pub-id></citation></ref><ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stappenbeck</surname><given-names>TS</given-names></name><name><surname>Hooper</surname><given-names>LV</given-names></name><name><surname>Gordon</surname><given-names>JI</given-names></name></person-group><article-title>Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2002</year><volume>99</volume><issue>24</issue><fpage>15451</fpage><lpage>15455</lpage><pub-id pub-id-type="pmid">12432102</pub-id></citation></ref><ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hooper</surname><given-names>LV</given-names></name><name><surname>Wong</surname><given-names>MH</given-names></name><name><surname>Thelin</surname><given-names>A</given-names></name><name><surname>Hansson</surname><given-names>L</given-names></name><name><surname>Falk</surname><given-names>PG</given-names></name><name><surname>Gordon</surname><given-names>JI</given-names></name></person-group><article-title>Molecular analysis of commensal host-microbial relationships in the intestine</article-title><source><italic>Science</italic></source><year>2001</year><volume>291</volume><issue>5505</issue><fpage>881</fpage><lpage>884</lpage><pub-id pub-id-type="pmid">11157169</pub-id></citation></ref><ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>B&#x000e4;ckhed</surname><given-names>F</given-names></name><name><surname>Manchester</surname><given-names>JK</given-names></name><name><surname>Semenkovich</surname><given-names>CF</given-names></name><name><surname>Gordon</surname><given-names>JI</given-names></name></person-group><article-title>Mechanisms underlying the resistance to diet-induced obesity in germ-free mice</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2007</year><volume>104</volume><issue>3</issue><fpage>979</fpage><lpage>984</lpage><pub-id pub-id-type="pmid">17210919</pub-id></citation></ref><ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ridlon</surname><given-names>JM</given-names></name><name><surname>Kang</surname><given-names>D-J</given-names></name><name><surname>Hylemon</surname><given-names>PB</given-names></name></person-group><article-title>Bile salt biotransformations by human intestinal bacteria</article-title><source><italic>Journal of Lipid Research</italic></source><year>2006</year><volume>47</volume><issue>2</issue><fpage>241</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">16299351</pub-id></citation></ref><ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>YH</given-names></name><name><surname>Kim</surname><given-names>JG</given-names></name><name><surname>Shin</surname><given-names>YW</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Whang</surname><given-names>KY</given-names></name></person-group><article-title>Effect of dietary inclusion of <italic>Lactobacillus acidophilus</italic> ATCC 43121 on cholesterol metabolism in rats</article-title><source><italic>Journal of Microbiology and Biotechnology</italic></source><year>2007</year><volume>17</volume><issue>4</issue><fpage>655</fpage><lpage>662</lpage><pub-id pub-id-type="pmid">18051279</pub-id></citation></ref><ref id="B47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>F-PJ</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Sprenger</surname><given-names>N</given-names></name><etal/></person-group><article-title>Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model</article-title><source><italic>Molecular Systems Biology</italic></source><year>2008</year><volume>4, article 157</volume><fpage>1</fpage><lpage>15</lpage></citation></ref><ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Norin</surname><given-names>E</given-names></name></person-group><article-title>Intestinal cholesterol conversion in adults and elderly from four different European countries</article-title><source><italic>Annals of Nutrition and Metabolism</italic></source><year>2008</year><volume>52</volume><issue>supplement 1</issue><fpage>12</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">18382071</pub-id></citation></ref><ref id="B49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H-Y</given-names></name><name><surname>Park</surname><given-names>J-H</given-names></name><name><surname>Seok</surname><given-names>S-H</given-names></name></person-group><article-title>Human originated bacteria, <italic>Lactobacillus rhamnosus</italic> PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice</article-title><source><italic>Biochimica et Biophysica Acta</italic></source><year>2006</year><volume>1761</volume><issue>7</issue><fpage>736</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">16807088</pub-id></citation></ref><ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bistrian</surname><given-names>B</given-names></name></person-group><article-title>Systemic response to inflammation</article-title><source><italic>Nutrition Reviews</italic></source><year>2007</year><volume>65</volume><issue>supplement 1</issue><fpage>170</fpage><lpage>172</lpage></citation></ref><ref id="B51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsukumo</surname><given-names>DML</given-names></name><name><surname>Carvalho-Filho</surname><given-names>MA</given-names></name><name><surname>Carvalheira</surname><given-names>JBC</given-names></name><etal/></person-group><article-title>Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance</article-title><source><italic>Diabetes</italic></source><year>2007</year><volume>56</volume><issue>8</issue><fpage>1986</fpage><lpage>1998</lpage><pub-id pub-id-type="pmid">17519423</pub-id></citation></ref><ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><article-title>Toll-like receptors in innate immunity</article-title><source><italic>International Immunology</italic></source><year>2005</year><volume>17</volume><issue>1</issue><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">15585605</pub-id></citation></ref><ref id="B53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Werner</surname><given-names>T</given-names></name><name><surname>Haller</surname><given-names>D</given-names></name></person-group><article-title>Intestinal epithelial cell signalling and chronic inflammation: from the proteome to specific molecular mechanisms</article-title><source><italic>Mutation Research</italic></source><year>2007</year><volume>622</volume><issue>1-2</issue><fpage>42</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">17628614</pub-id></citation></ref><ref id="B54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>LC</given-names></name><name><surname>Prince</surname><given-names>LR</given-names></name><name><surname>Sabroe</surname><given-names>I</given-names></name></person-group><article-title>Translational mini-review series on Toll-like receptors: networks regulated by Toll-like receptors mediate innate and adaptive immunity</article-title><source><italic>Clinical &#x00026; Experimental Immunology</italic></source><year>2007</year><volume>147</volume><issue>2</issue><fpage>199</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">17223959</pub-id></citation></ref><ref id="B55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>D</given-names></name><name><surname>Campbell</surname><given-names>JI</given-names></name><name><surname>King</surname><given-names>TP</given-names></name><etal/></person-group><article-title>Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-<italic>&#x003b3;</italic> and RelA</article-title><source><italic>Nature Immunology</italic></source><year>2003</year><volume>5</volume><issue>1</issue><fpage>104</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">14691478</pub-id></citation></ref><ref id="B56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neish</surname><given-names>AS</given-names></name><name><surname>Gewirtz</surname><given-names>AT</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><etal/></person-group><article-title>Prokaryotic regulation of epithelial responses by inhibition of I<italic>&#x003ba;</italic>B-<italic>&#x003b1;</italic> ubiquitination</article-title><source><italic>Science</italic></source><year>2000</year><volume>289</volume><issue>5484</issue><fpage>1560</fpage><lpage>1563</lpage><pub-id pub-id-type="pmid">10968793</pub-id></citation></ref><ref id="B57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Otte</surname><given-names>J-M</given-names></name><name><surname>Cario</surname><given-names>E</given-names></name><name><surname>Podolsky</surname><given-names>DK</given-names></name></person-group><article-title>Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells</article-title><source><italic>Gastroenterology</italic></source><year>2004</year><volume>126</volume><issue>4</issue><fpage>1054</fpage><lpage>1070</lpage><pub-id pub-id-type="pmid">15057745</pub-id></citation></ref><ref id="B58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name></person-group><article-title>Signaling pathways downstream of pattern-recognition receptors and their cross talk</article-title><source><italic>Annual Review of Biochemistry</italic></source><year>2007</year><volume>76</volume><fpage>447</fpage><lpage>480</lpage></citation></ref><ref id="B59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pietsch</surname><given-names>J</given-names></name><name><surname>Batra</surname><given-names>A</given-names></name><name><surname>Stroh</surname><given-names>T</given-names></name><etal/></person-group><article-title>Toll-like receptor expression and response to specific stimulation in adipocytes and preadipocytes: on the role of fat in inflammation</article-title><source><italic>Annals of the New York Academy of Sciences</italic></source><year>2006</year><volume>1072</volume><fpage>407</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">17057223</pub-id></citation></ref><ref id="B60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Batra</surname><given-names>A</given-names></name><name><surname>Pietsch</surname><given-names>J</given-names></name><name><surname>Fedke</surname><given-names>I</given-names></name><etal/></person-group><article-title>Leptin-dependent Toll-like receptor expression and responsiveness in preadipocytes and adipocytes</article-title><source><italic>The American Journal of Pathology</italic></source><year>2007</year><volume>170</volume><issue>6</issue><fpage>1931</fpage><lpage>1941</lpage><pub-id pub-id-type="pmid">17525261</pub-id></citation></ref><ref id="B61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siebler</surname><given-names>J</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Weber</surname><given-names>MM</given-names></name></person-group><article-title>The gut-liver-axis: endotoxemia, inflammation, insulin resistance and NASH</article-title><source><italic>Journal of Hepatology</italic></source><year>2008</year><volume>48</volume><issue>6</issue><fpage>1032</fpage><lpage>1034</lpage><pub-id pub-id-type="pmid">18468548</pub-id></citation></ref><ref id="B62"><label>62</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Delzene</surname><given-names>NM</given-names></name><name><surname>Neyrik</surname><given-names>AM</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Gibson</surname><given-names>GR</given-names></name><name><surname>Roberfroid</surname><given-names>M</given-names></name></person-group><article-title>Prebiotics and lipid metabolism: review of experimental and human data</article-title><source><italic>Handbook of Prebiotics</italic></source><year>2008</year><publisher-loc>Philadelphia, Pa, USA</publisher-loc><publisher-name>Taylor &#x00026; Francis</publisher-name><fpage>201</fpage><lpage>218</lpage></citation></ref><ref id="B63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calcinaro</surname><given-names>F</given-names></name><name><surname>Dionisi</surname><given-names>S</given-names></name><name><surname>Marinaro</surname><given-names>M</given-names></name><etal/></person-group><article-title>Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse</article-title><source><italic>Diabetologia</italic></source><year>2005</year><volume>48</volume><issue>8</issue><fpage>1565</fpage><lpage>1575</lpage><pub-id pub-id-type="pmid">15986236</pub-id></citation></ref><ref id="B64"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bleau</surname><given-names>C</given-names></name><name><surname>Lamontagne</surname><given-names>L</given-names></name><name><surname>Savard</surname><given-names>R</given-names></name></person-group><article-title>New <italic>Lactobacillus acidophilus</italic> isolates reduce the release of leptin by murine adipocytes leading to lower interferon-<italic>&#x003b3;</italic> production</article-title><source><italic>Clinical &#x00026; Experimental Immunology</italic></source><year>2005</year><volume>140</volume><issue>3</issue><fpage>427</fpage><lpage>435</lpage><pub-id pub-id-type="pmid">15932503</pub-id></citation></ref><ref id="B65"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naruszewicz</surname><given-names>M</given-names></name><name><surname>Johansson</surname><given-names>M-L</given-names></name><name><surname>Zapolska-Downar</surname><given-names>D</given-names></name><name><surname>Bukowska</surname><given-names>H</given-names></name></person-group><article-title>Effect of <italic>Lactobacillus plantarum</italic> 299v on cardiovascular disease risk factors in smokers</article-title><source><italic>American Journal of Clinical Nutrition</italic></source><year>2002</year><volume>76</volume><issue>6</issue><fpage>1249</fpage><lpage>1255</lpage><pub-id pub-id-type="pmid">12450890</pub-id></citation></ref><ref id="B66"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>S</given-names></name><name><surname>Saunier</surname><given-names>K</given-names></name><name><surname>Hanisch</surname><given-names>C</given-names></name><etal/></person-group><article-title>Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study</article-title><source><italic>Applied and Environmental Microbiology</italic></source><year>2006</year><volume>72</volume><issue>2</issue><fpage>1027</fpage><lpage>1033</lpage><pub-id pub-id-type="pmid">16461645</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Schematic diagram of themain metabolic pathways of dietary poly- and oligosaccharides in the gutecosystem.</p></caption><graphic xlink:href="IPID2008-829101.001"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Schematic diagram ofsignaling pathways triggered by bacterial components, saturated fatty acids, and adipokines in epithelial and innate immune cells leading toeither activation or negative regulation of proinflammatory pathways related toobesity and insulin resistance. (1) Lipopolysaccharide (LPS) from Gram-negativebacteria and saturated fatty acids (SFAs) is recognized by toll-like receptor(TLR) 4 activating proinflammatory pathways involving the MyD88 (myeloiddifferentiation primary-response protein 88)-dependent and -independentpathways that may lead to activation of nuclear factor (NF)-<italic>&#x003ba;</italic>B and activator protein-1 (AP-1) with productionof pro-inflammatory cytokines. (2) Peptidoglycan (PGL) and lipoteichoic acidfrom Gram-positive bacteria are recognized by TLR-2 triggering the activation ofthe MyD88-dependent pathway. (3) Commensal bacteria and some probiotics maysuppress activation of NF-<italic>&#x003ba;</italic>B cascade by (i) promotion of nuclear export ofNF-<italic>&#x003ba;</italic>B subunit relA in complex with PPAR-<italic>&#x003b3;</italic>; (ii) inhibition of I<italic>&#x003ba;</italic>B ubiquitination and degradation, (iii)induction of anti-inflammatory (IL10) cytokine production. (4) Leptin interactswith its receptors (OBR) activating the signal transducer and activator oftranscription (STAT), and induces production of CCL2, proinflammatorycytokines, and reactive oxygen species (ROS) causing endoplasmic reticulum (ER)stress.</p></caption><graphic xlink:href="IPID2008-829101.002"/></fig></floats-wrap></article>